[{"address1": "175 Innovation Boulevard", "city": "Wilmington", "state": "DE", "zip": "19805", "country": "United States", "phone": "302 467 1280", "website": "https://preludetx.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Dr. Krishna  Vaddi D.V.M., Ph.D.", "age": 57, "title": "Founder, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 905916, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Edna  Huang M.D.", "age": 50, "title": "President & Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 865629, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryant David Lim J.D.", "age": 52, "title": "Interim CFO, Chief Legal Officer & Corporate Secretary", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 586425, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Aimee  Crombie Ph.D.", "title": "Senior VP and Head of Strategic Planning & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Madhu  Pudipeddi Ph.D.", "title": "Senior Vice President of Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peggy A. Scherle Ph.D.", "age": 61, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 868617, "exercisedValue": 0, "unexercisedValue": 436567}, {"maxAge": 1, "name": "Lindsey  Trickett", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michele  Porreca M.B.A.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew P. Combs Ph.D.", "age": 56, "title": "Executive VP & Chief Chemistry Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 562461, "exercisedValue": 0, "unexercisedValue": 399432}, {"maxAge": 1, "name": "Mr. Naveen  Babbar Ph.D.", "title": "Senior Vice President of Translation Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 9, "governanceEpochDate": 1722470400, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.44, "open": 5.47, "dayLow": 4.99, "dayHigh": 5.61, "regularMarketPreviousClose": 5.44, "regularMarketOpen": 5.47, "regularMarketDayLow": 4.99, "regularMarketDayHigh": 5.61, "beta": 1.535, "forwardPE": -3.5416665, "volume": 78334, "regularMarketVolume": 78334, "averageVolume": 101419, "averageVolume10days": 139590, "averageDailyVolume10Day": 139590, "bid": 4.94, "ask": 5.3, "bidSize": 100, "askSize": 100, "marketCap": 280140960, "fiftyTwoWeekLow": 1.66, "fiftyTwoWeekHigh": 6.76, "fiftyDayAverage": 4.539, "twoHundredDayAverage": 3.956825, "currency": "USD", "enterpriseValue": 95856792, "floatShares": 13641758, "sharesOutstanding": 42079300, "sharesShort": 528272, "sharesShortPriorMonth": 566883, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0095999995, "heldPercentInsiders": 0.09086, "heldPercentInstitutions": 0.81464994, "shortRatio": 5.52, "shortPercentOfFloat": 0.0307, "bookValue": 3.837, "priceToBook": 1.3291634, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -125545000, "trailingEps": -1.86, "forwardEps": -1.44, "pegRatio": -0.1, "enterpriseToEbitda": -0.704, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "PRLD", "underlyingSymbol": "PRLD", "shortName": "Prelude Therapeutics Incorporat", "longName": "Prelude Therapeutics Incorporated", "firstTradeDateEpochUtc": 1601040600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b4d5f445-4c0f-32e5-9fdb-a86b330519d9", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.1, "targetHighPrice": 7.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.75, "targetMedianPrice": 4.5, "recommendationMean": 2.8, "recommendationKey": "hold", "numberOfAnalystOpinions": 4, "totalCash": 201924000, "totalCashPerShare": 3.676, "ebitda": -136188000, "totalDebt": 17640000, "quickRatio": 11.445, "currentRatio": 11.64, "debtToEquity": 8.371, "returnOnAssets": -0.38588002, "returnOnEquity": -0.65044, "freeCashflow": -65959624, "operatingCashflow": -108720000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-08-11"}]